Monoclonal antibodies are antibodies produced by a cloned cell that comes from a single precursor, or “clone” [1]. These antibodies are highly specific, allowing them to be used to treat a range of diseases. They can target specific molecules, such as viruses, tumor cells, or molecules involved in inflammation, unlike traditional therapies that target a broader range of cells and molecules.

Monoclonal antibodies (mAbs) have transformed modern medicine through their ability to target specific cells and molecules. Since their discovery in 1975, mAbs have been utilized across a broad range of therapeutic and diagnostic fields, demonstrating high specificity and efficacy [2]. These molecules have revolutionized the treatment of cancer, infectious diseases, autoimmune conditions, and other complex disorders, solidifying their role as indispensable tools in healthcare.

The rapid progress in biotechnology over recent decades has greatly enhanced the development and production of mAbs, leading to improved efficacy, safety, and accessibility of these biologics globally. However, despite global advancements, the application and development of monoclonal antibodies in Kazakhstan face significant challenges. These include the lack of local production infrastructure, limited accessibility of mAbs to patients, and underdeveloped scientific research and clinical trials in this field. Addressing these issues is critical to optimizing the use of mAbs for the benefit of the local population.

In this review we will explore recent trends and advancements in Mab therapy worldwide and in Kazakhstan

MYNGBAY A.

PhD, docent, K. Zhubanov Aktobe Regional University, Aktobe, Kazakhstan

E-mail: askhat.myngbay@zhubanov.edu.kz, https://orcid.org/0000-0002-3867-847X

BAIZAK A.N.

4th year BSc student, K. Zhubanov Aktobe Regional University, Aktobe, Kazakhstan

E-mail: alisherwmd@gmail.com, https://orcid.org/0009-0005-0288-8773

POSLUSHNAYA O.Y.

4th year BSc student, K. Zhubanov Aktobe Regional University, Aktobe, Kazakhstan

E-mail: poslushnaya_oksana@mail.ru, https://orcid.org/0009-0003-5162-4921

ALPYSBAEVA ZH.B.

4th year BSc student, K. Zhubanov Aktobe Regional University, Aktobe, Kazakhstan

E-mail: alpysbaeva222003@gmail.com, https://orcid.org/0009-0003-2325-533X

1. Rodríguez-Nava C, Ortuño-Pineda C, Illades-Aguiar B, Flores-Alfaro E, Leyva-Vázquez MA, Parra-Rojas I, del Moral-Hernández O, Vences-Velázquez A, Cortés-Sarabia K, Alarcón-Romero L del C. Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer. Biomedicines. 2023 Jun 1;11(6):1610.
2. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009 May;157(2):220–33.
3. The Story of César Milstein and Monoclonal Antibodies [Internet]. WhatisBiotechnology.org. [cited 2025 Mar 13]. Available from: https://www.whatisbiotechnology.org/
4. Araki K, Maeda R. A Brief Chronicle of Antibody Research and Technological Advances. Antibodies. 2024 Nov 11;13(4):90.
5. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020 Jan 2;27(1):1.
6. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019 Dec 20;7(6):e00535.
7. Marks L. Monoclonal antibodies and the transformation of blood typing. mAbs. 2014 Nov 3;6(6):1362.
8. Affiliate Clinic in Kazakhstan [Internet]. Biotherapy International. [cited 2025 Mar 13]. Available from: https://ibiotherapy.com/kazakhstan/
9. Pitiot A, Heuzé-Vourc’h N, Sécher T. Alternative Routes of Administration for Therapeutic Antibodies—State of the Art. Antibodies. 2022 Aug 26;11(3):56.
10. F.K.Smailova, R.H.Karaev, R.A.Dulazov, H.V.Bakirov, B.A.Sazhanov. Opyt primeneniya preparata infliksimab pri nespecificheskom yazvennom kolite: klinicheskoe nablyudenie. Vestnik Kazahskogo Nacional'nogo Medicinskogo Universiteta. 2015;(2):537–40.
11. Ivanova R, Goremykina M, Glushkova N, Vento S. Successful Use of a Reduced Dose Regimen of Rituximab in a Case of Rheumatoid Arthritis with Raynaud’s Syndrome. Isr Med Assoc J IMAJ. 2018 Jan;20(1):64–5.
12. Murzabayeva M. Efficacy of golimumab in the treatment of ankylosing spondylitis and rheumatoid arthritis (own experience). Медицина. 2020 Dec 13;5–6:24–31.
13. Tsiogka A, Bauer JW, Patsatsi A. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature. Acta Derm Venereol. 2021 Jan 20;101(1):1497.
14. Li H, Tsokos GC. IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases. Clin Rev Allergy Immunol. 2021 Feb;60(1):31–45.
15. Wang J, Zhou X, Elazab ST, Huang J, Hsu WH. Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine. Anim Open Access J MDPI. 2025 Feb 7;15(4):472.
16. Hughes R, Whitley L, Fitovski K, Schneble HM, Muros E, Sauter A, Craveiro L, Dillon P, Bonati U, Jessop N, Pedotti R, Koendgen H. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord. 2021 Apr 1;49:102725.
17. Vasudeva A, Yadav SL, Nanda S, Sahu S. Assessment of pain and structure after an intra-articular injection of adalimumab in osteoarthritis of the knee. Medicine (Baltimore). 2020 Jul 10;99(28):e21131.
18. Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, Sergeeva M, Saake M, Garcia M, Kollias G, Straub RH, Sporns O, Doerfler A, Brune K, Schett G. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3731–6.
19. Spałek MM, Jałowska M, Bowszyc-Dmochowska M, Dmochowski M. Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center. Medicina (Mex). 2024 Feb 4;60(2):270.

Monoclonal antibody;, therapy;, autoimmune disease; , application; , development